戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 osaconazole, anidulafungin, caspofungin, and micafungin.
2 hinocandins, anidulafungin, caspofungin, and micafungin.
3 sceptible to caspofungin, anidulafungin, and micafungin.
4 chinocandins anidulafungin, caspofungin, and micafungin.
5 spp. against anidulafungin, caspofungin, and micafungin.
6 le-resistant Candida isolates tested against micafungin.
7 (about 40% response rate) and the second was micafungin.
8             All isolates were susceptible to micafungin.
9 cafungin treatment than it was in absence of micafungin.
10 sporium spp. and L. prolificans, followed by micafungin.
11 ar, although kidney function was better with micafungin.
12  errors (26.7%) in testing anidulafungin and micafungin.
13 ida spp. were tested against caspofungin and micafungin.
14 tivity of the antifungals amphotericin B and micafungin.
15  (97.4%); caspofungin, 0.12/0.5 (98.0%); and micafungin, 0.25/1 (99.2%).
16 e to echinocandins (anidulafungin [2.4%] and micafungin [1.9%]) and azoles (3.5 to 5.6%) was most pre
17 s were randomized 1:1 to receive intravenous micafungin 100 mg or center-specific standard care (fluc
18      Interventions: Empirical treatment with micafungin (100 mg, once daily, for 14 days) (n = 131) v
19 sessed a preemptive antifungal approach with micafungin (100 mg/d) in intensive care unit patients re
20 1 isolates), caspofungin (300 isolates), and micafungin (102 isolates) as determined by CLSI broth mi
21 ull analysis set comprised 344 patients (172 micafungin; 172 standard care).
22 ravenous micafungin (>/=5 doses of >/=300 mg micafungin 2-3 times weekly) in patients with acute leuk
23 ents received >75% of their course as 300 mg micafungin 3 times weekly.
24 bited higher tolerance to fluconazole (FLC), micafungin, 5- flucytosine and amphotericin B compared t
25 d), caspofungin (1,447 isolates tested), and micafungin (539 isolates tested), respectively.
26 ediate or resistant) to both caspofungin and micafungin, 54 (90.0%) contained a mutation in fks1 or f
27  received intermittent high-dose intravenous micafungin, 83 (79.8%) as prophylaxis.
28 .3% for standard care (Delta standard care - micafungin [95% confidence interval], 0.7% [-2.7% to 4.4
29        We studied the antifungal activity of micafungin, a new echinocandin, in combination with ravu
30 ographic regions, there was no difference in micafungin activity across the regions.
31       We determined the in vitro activity of micafungin against 2,656 invasive (bloodstream or steril
32 ctivities of anidulafungin, caspofungin, and micafungin against 5,346 invasive (bloodstream or steril
33 ctivities of anidulafungin, caspofungin, and micafungin against 526 isolates of Aspergillus spp. (64
34 akpoints for anidulafungin, caspofungin, and micafungin against Candida species.
35 hotericin B, anidulafungin, caspofungin, and micafungin against invasive, unique patient isolates of
36  for the emergence of in vitro resistance to micafungin among invasive Candida sp. isolates is indica
37 on, 17 days), clinical success was 98.6% for micafungin and 99.3% for standard care (Delta standard c
38 after 24 h of incubation for caspofungin and micafungin and after 48 h of incubation for posaconazole
39 labrata, from 2.4% (2004) to 5.7% (2009) for micafungin and C. krusei, and from 0.0% (2004) to 3.1% (
40 sei, and from 0.0% (2004) to 3.1% (2009) for micafungin and C. parapsilosis.
41  synergizes with cell wall stressors such as micafungin and calcofluor white in preventing yeast grow
42                    We determined the MICs of micafungin and caspofungin against 315 invasive clinical
43 osomal amphotericin B (L-AmB), itraconazole, micafungin and placebo.
44 ncidences of drug-related adverse events for micafungin and standard care were 11.6% and 16.3%, leadi
45 ophylaxis included vancomycin, cefazolin and micafungin and was adjusted based on peritransplant cult
46 hinocandins (anidulafungin, caspofungin, and micafungin) and FKS1 and FKS2 gene sequences were determ
47  99.3% (anidulafungin) to 100% (caspofungin, micafungin) and interlaboratory reproducibility was 99%.
48 osaconazole, caspofungin, anidulafungin, and micafungin) and interpreted the MICs according to the EU
49 nd BMD were 99.8% for caspofungin, 98.2% for micafungin, and 98.1% for posaconazole.
50                  Echinocandins (caspofungin, micafungin, and anidulafungin) exert their fungicidal ac
51 oconazole, one with itraconazole, three with micafungin, and one with caspofungin) including 2,792 pa
52 ansplant recipients received 7 to 10 days of micafungin, and only patients with growth of yeast or mo
53 d the most potent activity were caspofungin, micafungin, and terbinafine, while amphotericin B showed
54 e, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine.
55 omparator drugs amphotericin B, caspofungin, micafungin, and voriconazole were also determined.
56                      The echinocandin drugs (micafungin, anidulafungin, and caspofungin) are the pref
57 iewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole
58                 Compared with ABLC, however, micafungin appeared to be associated with lower early-re
59 pofungin MIC values, we evaluated the use of micafungin as a surrogate marker to predict the suscepti
60  candidiasis responds to escalating doses of micafungin as effectively as fluconazole.
61 (0.2% VMEs and MEs, 0.8% minor errors) using micafungin as the surrogate marker.
62                   With either caspofungin or micafungin as the test reagent, the CLSI method identifi
63 for Candida parapsilosis when caspofungin or micafungin but not anidulafungin was used as the compara
64 ed for all three FDA-approved echinocandins (micafungin, caspofungin, and anidulafungin).
65 iple organ failure, empirical treatment with micafungin, compared with placebo, did not increase fung
66  of the T2Candida panel; however, the use of micafungin continued to decline after the panel was remo
67 al, demonstrated that a single large dose of micafungin could clear disseminated candidiasis, even th
68                             Use of empirical micafungin decreased the rate of new invasive fungal inf
69                                   The use of micafungin did not affect the findings.
70 nce of IC was 8.9% for placebo and 11.1% for micafungin (difference, 2.24%; [95% confidence interval,
71                              Duration and/or micafungin dosing algorithms were not associated with li
72                     Large variability in the micafungin dosing regimen was observed; 78 (75%) patient
73  studies of micafungin that examined optimal micafungin dosing strategies.
74 dynamics studies confirmed this link between micafungin efficacy and the ratio of the area under the
75                                              Micafungin exhibited linear plasma pharmacokinetics in t
76                       The median duration of micafungin exposure prior to breakthrough was 33 days (r
77 y immunosuppressed patients with heavy prior micafungin exposure.
78 t 7 antifungals (anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posaconazole, and
79 , resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9%
80  day 28, there were 82 (68%) patients in the micafungin group vs 79 (60.2%) in the placebo group who
81 l infection in 4 of 128 patients (3%) in the micafungin group vs placebo (15/123 patients [12%]) (P =
82 ean age 63 years; 91 [35%] women), 251 (128, micafungin group; 123, placebo group) were included in t
83 tent administration of high-dose intravenous micafungin (>/=5 doses of >/=300 mg micafungin 2-3 times
84                                              Micafungin had good in vitro activity against all flucon
85 aconazole, itraconazole, amphotericin B, and micafungin had the most potent in vitro activity.
86 ar disseminated candidiasis, even though the micafungin half-life in such animals is shorter than in
87                         The new echinocandin micafungin has excellent in vitro activity against 315 i
88                                              Micafungin has excellent in vitro activity against invas
89             To facilitate rapid detection of micafungin heteroresistance in C. parapsilosis, we const
90 , Europe and Asia, we demonstrate widespread micafungin heteroresistance in C. parapsilosis.
91 tion for invasive infections, fail to detect micafungin heteroresistance in C. parapsilosis.
92 the pharmacokinetics and pharmacodynamics of micafungin in a rabbit model of neonatal HCME and bridge
93  provide a foundation for clinical trials of micafungin in neonates with HCME and a model for antimic
94                             The half-life of micafungin in patient blood was 14 hours in several stud
95 ia/invasive candidiasis to inform the use of micafungin in pediatric patients younger than 4 months,
96  concentrations, but M2 was more tolerant to micafungin in vitro.
97                                              Micafungin is a new echinocandin exhibiting broad-spectr
98                                              Micafungin is an echinocandin antifungal agent that has
99 idiasis, antifungal therapy with intravenous micafungin is dosed daily.
100 11.4% VME, 0.09% ME, and 0.19% miE); and for micafungin, it was 99.6% (14.3% VME, 0.15% ME, and 0.17%
101                                              Micafungin may prove useful in the treatment of infectio
102                                              Micafungin may serve as an acceptable surrogate marker f
103  for anidulafungin (ANF), caspofungin (CSF), micafungin (MCF), fluconazole (FLC), posaconazole (PSC),
104  with the echinocandins caspofungin (CSF) or micafungin (MCF).
105 0.015 microg/ml; MEC90, 0.03 microg/ml), and micafungin (MEC50, 0.007 microg/ml; MEC90, 0.015 microg/
106 , and safety of alternate dosing regimens of micafungin (MFG) for the treatment of experimental subac
107 e-resistant Candida spp. were inhibited at a micafungin MIC that was </=1 microg/ml.
108  of anidulafungin (MIC(90), 0.06 microg/ml), micafungin (MIC(90), 0.12 microg/ml) or caspofungin (MIC
109 C50, 0.03 microg/ml; MIC90, 0.25 microg/ml), micafungin (MIC50, 0.015 microg/ml; MIC90, 1 microg/ml).
110 collection, C. glabrata exhibited the lowest micafungin MICs (MIC(90), </=0.015 microg/ml), followed
111 2 system reliably determined caspofungin and micafungin MICs among Candida spp. and posaconazole MICs
112 ype MIC distribution is also responsible for micafungin MICs of >2 microg/ml and clinical breakthroug
113 , 5 (including all C. glabrata isolates) had micafungin MICs of >2 microg/ml, but all demonstrated ca
114 ngin MICs of 0.5 to 1 microg/ml, but 4/5 had micafungin MICs of >2 microg/ml.
115 fungin MICs were >/=0.5 mug/ml and for which micafungin MICs were >/=0.25 mug/ml were considered resi
116 n or wild-type C. parapsilosis with elevated micafungin MICs.
117  amphotericin B with significant increase in micafungin minimum inhibitory concentration.
118 bserved, most often representing failures of micafungin (n = 16) and aerosolized amphotericin B (n =
119                    Targeted prophylaxis with micafungin or ABLC decreased the risk of mycoses in high
120 cacy and safety of targeted prophylaxis with micafungin or amphotericin B lipid complex (ABLC) was as
121                           Preincubation with micafungin or anidulafungin had similar effects on PMN-i
122                                              Micafungin or caspofungin can also be used as a surrogat
123                       Thus, a single dose of micafungin, or 2 such doses within a few days of each ot
124                                              Micafungin penetrated most compartments of the central n
125          In high-risk allo-HCT recipients on micafungin prophylaxis, we show that heteroresistance (t
126         In nondialyzed patients, ABLC versus micafungin recipients had significantly higher serum cre
127 l infections developed in 11.1% (2 of 18) of micafungin recipients, 8.3% (2 of 24) of ABLC recipients
128    Objective: To determine whether empirical micafungin reduces invasive fungal infection (IFI)-free
129                                              Micafungin resistance was rare, but intermediate suscept
130 microg/ml of anidulafungin, caspofungin, and micafungin, respectively) were as follows: for C. albica
131 ntheses) for anidulafungin, caspofungin, and micafungin, respectively, were as follows: 0.12 (99.7%),
132 per year for anidulafungin, caspofungin, and micafungin, respectively, were as follows: for C. albica
133 resistant to anidulafungin, caspofungin, and micafungin, respectively.
134 d M27-A3 for anidulafungin, caspofungin, and micafungin susceptibility testing of 133 clinical isolat
135 udies, and maximum-tolerated-dose studies of micafungin that examined optimal micafungin dosing strat
136 idiasis (IC) breaking through >or=3 doses of micafungin therapy during the first 28 months of its use
137 pretive criteria were compared with those of micafungin to determine the percent categorical agreemen
138 2 mug/ml for caspofungin and 0.03 mug/ml for micafungin to differentiate wild-type (WT) from non-WT s
139 X (INTENSE) study into the preemptive use of micafungin to prevent invasive candidiasis (IC) after ab
140 he INTENSE study into the pre-emptive use of micafungin to prevent invasive candidosis (IC) post abdo
141                              Caspofungin- or micafungin-treated conidia and germlings induced less se
142  analysis set comprised 124 placebo- and 117 micafungin-treated patients.
143                           Breakthrough IC on micafungin treatment occurred predominantly in severely
144 mpetitive with M1 in mouse kidneys following micafungin treatment than it was in absence of micafungi
145  isolates and outcomes in patients receiving micafungin treatment.
146 ains against anidulafungin, caspofungin, and micafungin, using CLSI M27-A3 broth microdilution (BMD)
147                                              Micafungin versus ABLC recipients were older (P=0.0065)
148 ficantly different when compared between the micafungin vs placebo groups (HR, 1.69 [95% CI, 0.96-2.9
149               Noninferiority (10% margin) of micafungin vs standard care was assessed in the per prot
150 milar but creatinine clearance was higher in micafungin- vs standard care-treated patients.
151                                              Micafungin was noninferior to standard care as antifunga
152                                              Micafungin was not reliably found in cerebrospinal fluid
153                                     Overall, micafungin was very active against Candida (MIC50/MIC at
154 te, intermittent administration of high-dose micafungin was well tolerated, without any associated li
155  Vitek 2 and BMD methods for caspofungin and micafungin were 99.5% and 98.6%, respectively.
156 ped ECVs for anidulafungin, caspofungin, and micafungin were applied to 15,269 isolates of Candida sp
157 voriconazole, posaconazole, caspofungin, and micafungin were assessed for 290 clinical isolates of th
158 oriconazole, anidulafungin, caspofungin, and micafungin were determined by CLSI broth microdilution m
159  resistant to anidulafungin, caspofungin, or micafungin were shown to have fks mutations.
160          With the exception that the MICs of micafungin were significantly lower, the calculated aver
161 conis isolates revealed that terbinafine and micafungin were the most active drugs.
162 ts ranged from 89.5% (caspofungin) to 99.2% (micafungin), whereas the EA between the Etest and CLSI r
163 oriconazole, anidulafungin, caspofungin, and micafungin, while a provisional susceptibility breakpoin

 
Page Top